TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6101516

Group type: EXPERIMENTAL
Intervention: Propranolol maintained until the day of surgery, half the usual dose given 2 hours prior to surgery, and intravenous propranolol administered every four hours postoperatively (group IV, n=19)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Propranolol abruptly withdrawn 48 hours prior to surgery (group II, n=17)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Propranolol abruptly withdrawn 10 hours prior to surgery (group III, n=18)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No propranolol therapy (group I, n=17)
Number of subjects: 54
Study: 31707324

Group type: EXPERIMENTAL
Intervention: Overweight (BMI 25-29.9 kg/m2)
Number of subjects: 14534

Group type: EXPERIMENTAL
Intervention: Obese class I (BMI 30-34.9 kg/m2)
Number of subjects: 14534

Group type: COMPARATOR
Intervention: Underweight/normal weight (BMI <25 kg/m2)
Number of subjects: 14534
Study: 30580198

Group type: EXPERIMENTAL
Intervention: Anxiolytics
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: BISS anxiety subscale
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: BISS anxiety score at baseline
Number of subjects: 482
Study: 28377173

Group type: EXPERIMENTAL
Intervention: Alfacalcidol 1 μg daily for 4 months
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard asthma treatment only
Number of subjects: 82
Study: 25415205

Group type: EXPERIMENTAL
Intervention: Self-reported sedentary time on weekdays
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Accelerometer-measured sedentary time
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Self-reported sedentary time
Number of subjects: 230

Group type: COMPARATOR
Intervention: Accelerometer-measured sedentary time on weekdays vs. weekend days
Number of subjects: 230
Study: 23319437

Group type: EXPERIMENTAL
Intervention: L-arginine (ARG; 0.075 g·kg‐1 body mass)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: L-arginine (ARG)
Number of subjects: 15
Study: 21608216

Group type: EXPERIMENTAL
Intervention: Total glucosides of paeony (TGP) for 5 years (TGP1 group)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Total glucosides of paeony (TGP) for 1-5 years (TGP2 group)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (matched patients)
Number of subjects: 96
Study: 19711141

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 630
Study: 17370493

Group type: EXPERIMENTAL
Intervention: Auricular point magnetotherapy (sticking magnetic bead of 66 gauss each piece with no pressing)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Auricular sticking of Vaccaria seed with no pressing
Number of subjects: 60
Study: 15331203

Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (1000 kcal per day, protein:carbohydrate:fat = 25:40:35)
Number of subjects: 22

Group type: COMPARATOR
Intervention: High carbohydrate diet (1000 kcal per day, protein:carbohydrate:fat = 25:65:10)
Number of subjects: 22
Study: 12003104

Group type: EXPERIMENTAL
Intervention: Weight loss (11.3±6.9 kg after 1 year)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Before weight loss measurements
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: After weight loss measurements
Number of subjects: 34
Study: 9457092

Group type: EXPERIMENTAL
Intervention: Active warfarin and active aspirin (WA)
Number of subjects: 5499

Group type: COMPARATOR
Intervention: Active warfarin (W)
Number of subjects: 5499

Group type: COMPARATOR
Intervention: Active aspirin (A)
Number of subjects: 5499

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 5499

Group type: COMPARATOR
Intervention: Warfarin or aspirin
Number of subjects: 5499
Study: 7616989

Group type: EXPERIMENTAL
Intervention: Zidovudine (250 mg twice daily)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 77
Study: 2911965

Group type: EXPERIMENTAL
Intervention: Biphasic 12 msec truncated exponential waveform
Number of subjects: 21

Group type: COMPARATOR
Intervention: Monophasic truncated exponential waveform
Number of subjects: 21
Study: 201111

Group type: EXPERIMENTAL
Intervention: D-thyroxin (4 mg/die)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 30624885

Group type: EXPERIMENTAL
Intervention: Bicyclic RGD peptides (e.g., CT3HPQcT3RGDcT3, CT3HPQCT3RGDcT3, CT3HSQCT3RGDcT3)
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Cy5-labeled bicycle CT3HPQcT3RGDcT3
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: RGD 'knottin' peptide
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: In vitro staining of HT29 cells with Cy5-labeled bicycles
Number of subjects: 672
Study: 28651514

Group type: EXPERIMENTAL
Intervention: Balanced crystalloid solution (Plasma-Lyte 148)
Number of subjects: 11000

Group type: COMPARATOR
Intervention: Saline (0.9% sodium chloride)
Number of subjects: 11000
Study: 26049181

Group type: COMPARATOR
Intervention: 200 mg/d hydrocortisone intravenous infusion lasting for 2 hours (control group)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 8.33 mg/h hydrocortisone per hour with an intravenous pump (research group)
Number of subjects: 79
Study: 23915054

Group type: EXPERIMENTAL
Intervention: Attend condition (target letters in specified color)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ignore condition (letters in different color)
Number of subjects: 3
Study: 21153471

Group type: EXPERIMENTAL
Intervention: Burch procedure
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Autologous fascia sling procedure
Number of subjects: 280
Study: 18586692

Group type: EXPERIMENTAL
Intervention: Higher levels of insight at baseline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More positive medication attitudes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change in insight scores over time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change toward more positive medication attitudes
Number of subjects: 0
Study: 16107544

Group type: EXPERIMENTAL
Intervention: Self-directed cognitive-behavioral intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: PedsQL 4.0
Number of subjects: 40
Study: 15220594

Group type: EXPERIMENTAL
Intervention: Untreated silicone breast implant rupture
Number of subjects: 271

Group type: COMPARATOR
Intervention: Intact silicone breast implants
Number of subjects: 271
Study: 12208405

Group type: EXPERIMENTAL
Intervention: Enoxaparin (1 mg/kg given as twice daily subcutaneous injections)
Number of subjects: 1326

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 1326
Study: 9643402

Group type: EXPERIMENTAL
Intervention: Fetuses with ARED flow
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Fetuses born alive with ARED flow
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Group with absent end-diastolic flow at first examination and then reversed flow until delivery
Number of subjects: 88
Study: 7814306

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: Non-exercise condition
Number of subjects: 6

Group type: COMPARATOR
Intervention: Less vigorous antecedent conditions
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Aerobic exercise before vocational task
Number of subjects: 6
Study: 2759546

Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide‐5‐mononitrate (1-hour post-administration)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide‐5‐mononitrate (7-day administration)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 356719

Group type: EXPERIMENTAL
Intervention: Prazosin (1-2 mg t.i.d.)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Prazosin + Hydrochlorothiazide (25 mg daily for 3 weeks)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Prazosin + Hydrochlorothiazide + Clonidine (low doses for 6 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 31769875

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 215

Group type: COMPARATOR
Intervention: Platinum-pemetrexed
Number of subjects: 215

Group type: COMPARATOR
Intervention: Cobas plasma
Number of subjects: 215

Group type: COMPARATOR
Intervention: ddPCR
Number of subjects: 215

Group type: COMPARATOR
Intervention: NGS
Number of subjects: 215
Study: 30706944

Group type: EXPERIMENTAL
Intervention: Randomization statistics
Number of subjects: 0
Study: 29349510

Group type: EXPERIMENTAL
Intervention: Early preventive rehabilitation lasting 12 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Current standard care with no formal shoulder exercise
Number of subjects: 76
Study: 27194393

Group type: EXPERIMENTAL
Intervention: Self-regulated modified constraint-induced movement therapy (SR-mCIMT)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional functional rehabilitation
Number of subjects: 86

Group type: COMPARATOR
Intervention: Modified constraint-induced movement therapy (mCIMT)
Number of subjects: 86
Study: 25208853

Group type: EXPERIMENTAL
Intervention: Multicomponent school-based intervention promoting healthy eating and physical activity
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8
Study: 22240553

Group type: EXPERIMENTAL
Intervention: Graduated compression garments worn continuously for 24 hours after initial 40-km time trial
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo garment (noncompressive) worn continuously for 24 hours after initial 40-km time trial
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Graduated compression garments
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo garment
Number of subjects: 14
Study: 20558084

Group type: EXPERIMENTAL
Intervention: Antibody-directed therapy (rituximab and intravenous immune globulin (IVIG), or IVIG alone)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Successful depletion of DSA
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Treatment for DSA
Number of subjects: 116

Group type: COMPARATOR
Intervention: No DSA
Number of subjects: 116
Study: 17368327

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 48

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 48
Study: 15825576

Group type: EXPERIMENTAL
Intervention: Aerosol application of Quixil sealant at the operative site
Number of subjects: 64

Group type: COMPARATOR
Intervention: Merocel nasal packing
Number of subjects: 64
Study: 11996160

Group type: EXPERIMENTAL
Intervention: Metronidazole gel
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 6
Study: 10071982

Group type: COMPARATOR
Intervention: Capecitabine 1250 mg/m2 alone (treatment A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Capecitabine 1250 mg/m2 followed immediately by Maalox (treatment B)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Capecitabine 1250 mg/m2 followed 2 hours later by Maalox (treatment C)
Number of subjects: 12
Study: 7551385

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (O2) delivered via nasal cannula at 1 L/min for 4 hours
Number of subjects: 23

Group type: COMPARATOR
Intervention: Room air delivered via nasal cannula at 1 L/min for 4 hours
Number of subjects: 23
Study: 1971651

Group type: EXPERIMENTAL
Intervention: Single pre-operative dose of 1 g ceftazidime (im or iv) 1 hour before surgery
Number of subjects: 120

Group type: COMPARATOR
Intervention: Three peri-operative doses of 1 g ceftazidime (im or iv) 1 hour before, and 6 and 12 hours after surgery
Number of subjects: 120
Study: 6992979

Group type: EXPERIMENTAL
Intervention: Localized radiotherapy (4000 rad)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Extensive radiotherapy including brain, adrenals, and upper retroperitoneal lymph nodes
Number of subjects: 114
Study: 30395857

Group type: EXPERIMENTAL
Intervention: Nonheparin coating (Balance; Medtronic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin‐based coating (Carmeda; Medtronic)
Number of subjects: 0
Study: 29019557

Group type: EXPERIMENTAL
Intervention: CO2 Group
Number of subjects: 210

Group type: COMPARATOR
Intervention: Air Group
Number of subjects: 210
Study: 25730652

Group type: EXPERIMENTAL
Intervention: Cycling with superimposed electromyostimulation (C+E)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Cycling (C)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Electromyostimulation (E)
Number of subjects: 13
Study: 25393603

Group type: EXPERIMENTAL
Intervention: Qualitative visual feedback (Group 1)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Qualitative and quantitative visual feedback (Group 2)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Comparison of Group 2 to Group 1
Number of subjects: 97
Study: 22863562

Group type: EXPERIMENTAL
Intervention: PNPLA3 SNP rs738409
Number of subjects: 1532

Group type: EXPERIMENTAL
Intervention: PNPLA3 SNP rs2281135
Number of subjects: 1532

Group type: EXPERIMENTAL
Intervention: Sex-specific association
Number of subjects: 1532
Study: 19653486

Group type: EXPERIMENTAL
Intervention: Congruent auditory cues
Number of subjects: 0

Group type: COMPARATOR
Intervention: Incongruent auditory cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Egocentric auditory cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exocentric auditory cues
Number of subjects: 0
Study: 17461296

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/day
Number of subjects: 6600

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/day in patients with type 2 diabetes
Number of subjects: 6600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6600
Study: 16118611

Group type: EXPERIMENTAL
Intervention: O2/N2O mixture
Number of subjects: 34

Group type: COMPARATOR
Intervention: O2/air mixture
Number of subjects: 34
Study: 12064363

Group type: EXPERIMENTAL
Intervention: G‐CSF donor priming (3 to 4 micro/kg per day for 7 days prior to marrow harvest)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: G‐CSF donor priming
Number of subjects: 50
Study: 9800936

Group type: EXPERIMENTAL
Intervention: Antibodies against copper-oxidised LDL
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Antibodies against MDA-LDL
Number of subjects: 34
Study: 7895137

Group type: EXPERIMENTAL
Intervention: Computer-generated informational message directed to physicians regarding average LOS and current LOS.
Number of subjects: 14099

Group type: COMPARATOR
Intervention: No message (control group).
Number of subjects: 14099
Study: 1637878

Group type: EXPERIMENTAL
Intervention: Penicillin G
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cotrimoxazole
Number of subjects: 48
Study: 6541714

Group type: EXPERIMENTAL
Intervention: Intravenous amphotericin B
Number of subjects: 32

Group type: COMPARATOR
Intervention: Central venous catheter removal
Number of subjects: 32
Study: 30659057

Group type: EXPERIMENTAL
Intervention: Buttonhole cannulation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Stepladder cannulation
Number of subjects: 50
Study: 30053893

Group type: EXPERIMENTAL
Intervention: m-learning intervention (HiSense APP-ID)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study: 27273951

Group type: EXPERIMENTAL
Intervention: Conformal radiotherapy combined with radiofrequency hyperthermia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conformal radiotherapy
Number of subjects: 80
Study: 25358451

Group type: EXPERIMENTAL
Intervention: Early tracheotomy (performed before day eight of MV)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Late tracheotomy (performed from day 14 if still indicated)
Number of subjects: 489
Study: 23757474

Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (CHO) - 800 mL the evening before and 400 mL 2 hours before surgery
Number of subjects: 38

Group type: COMPARATOR
Intervention: Fasting (FAST) - standard hospital protocol
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (CHO)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Fasting (FAST)
Number of subjects: 38
Study: 19933596

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) at a target dose of 3.0 g/day
Number of subjects: 370

Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (IVC) at a dose of 0.5‐1.0 g/m(2)/month
Number of subjects: 370

Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (IVC)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) and intravenous cyclophosphamide (IVC)
Number of subjects: 370
Study: 18172030

Group type: EXPERIMENTAL
Intervention: ICD for primary prevention
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: ICD for secondary prevention
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: ICD
Number of subjects: 121
Study: 16367881

Group type: EXPERIMENTAL
Intervention: BIAsp 30 plus metformin
Number of subjects: 341

Group type: COMPARATOR
Intervention: BIAsp 30 only
Number of subjects: 341

Group type: COMPARATOR
Intervention: Glibenclamide plus metformin
Number of subjects: 341
Study: 12679163

Group type: EXPERIMENTAL
Intervention: Nutritional supplement (400 kcal, 15 g protein, 50% of vitamin DRVs) and resistance exercise training
Number of subjects: 108

Group type: COMPARATOR
Intervention: No supplementation or training (control group)
Number of subjects: 108
Study: 11147228

Group type: EXPERIMENTAL
Intervention: Various treatment protocols for remission induction and postremission treatment in ALL
Number of subjects: 0
Study: 9377606

Group type: EXPERIMENTAL
Intervention: Losartan (10 to 150 mg once daily, most commonly 50 to 100 mg per day)
Number of subjects: 3800

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 3800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3800

Group type: COMPARATOR
Intervention: Losartan and Placebo
Number of subjects: 3800
Study: 8506804

Group type: EXPERIMENTAL
Intervention: ProAg catheter (Foley catheter coated with silver-protein)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual latex Foley catheter
Number of subjects: 0
Study: 3470323

Group type: EXPERIMENTAL
Intervention: Viadent containing 0.03% sanguinaria extract (0.01% sanguinarine chloride)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hibitane Dental containing 0.2% chlorhexidine gluconate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Experimental rinse with a tripled concentration of sanguinarine chloride
Number of subjects: 12
Study: 30032888

Group type: EXPERIMENTAL
Intervention: Visual preconditioning (eyepatch application for ≥3 hours the day before surgery)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Programmed explanation the day before surgery (Control)
Number of subjects: 179
Study: 27174798

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 2725

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 2725
Study: 24314696

Group type: EXPERIMENTAL
Intervention: Out-of-plane approach (needle inserted at a 45‐60° angle 1cm caudal to the midpoint of the ultrasound probe just above the femoral nerve)
Number of subjects: 44

Group type: COMPARATOR
Intervention: In-plane approach (needle inserted 0.2‐0.4 cm from the side of the probe lateral to the femoral nerve)
Number of subjects: 44
Study: 22227229

Group type: EXPERIMENTAL
Intervention: mpHBV (modified process hepatitis B vaccine)
Number of subjects: 566

Group type: COMPARATOR
Intervention: Control (RECOMBIVAX‐HB™)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: mpHBV
Number of subjects: 566

Group type: COMPARATOR
Intervention: Control
Number of subjects: 566

Group type: COMPARATOR
Intervention: mpHBV and Control
Number of subjects: 566
Study: 20118146

Group type: EXPERIMENTAL
Intervention: Intranasal application of xenon at a rate of 1.0 litre h(‐1) for 30 min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 17353472

Group type: EXPERIMENTAL
Intervention: rtPA (recombinant tissue plasminogen activator)
Number of subjects: 1367
Study: 15911152

Group type: EXPERIMENTAL
Intervention: Flexible-dose pregabalin (150, 300, 450, and 600 mg/day with weekly dose escalation)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Fixed-dose pregabalin (300 mg/day for 1 week followed by 600 mg/day for 11 weeks)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study: 12225612

Group type: EXPERIMENTAL
Intervention: Antithrombin III
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8143220

Group type: EXPERIMENTAL
Intervention: Sotalol (173.3 +/- 59.8 mg/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (13 on amiodarone and 3 on beta-blockers)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 31
Study: 3061308

Group type: EXPERIMENTAL
Intervention: Rigid gas-permeable (RGP) lenses (Boston IV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrogel lenses (Bausch & Lomb 'O' series)
Number of subjects: 0
Study: 30908577

Group type: EXPERIMENTAL
Intervention: 10 kHz stimulation (high-frequency [HF])
Number of subjects: 99

Group type: COMPARATOR
Intervention: 10-1,500 Hz stimulation (low-frequency [LF])
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both HF and LF stimulation
Number of subjects: 99
Study: 27862905

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (INF) 2 μg/kg, maximum 100 μg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (intranasal saline)
Number of subjects: 49
Study: 25631503

Group type: EXPERIMENTAL
Intervention: Health education once a week (Group C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health education once every ten days (Group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health education once a month (Group A)
Number of subjects: 0
Study: 23082885

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transfusion of previously frozen apheresis platelets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no ASA therapy)
Number of subjects: 0
Study: 21277160

Group type: EXPERIMENTAL
Intervention: Insall‐Burstein II (Zimmer, Warsaw, IN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Press Fit Condylar Modular (Johnson & Johnson, Raynham, MA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 19635160

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 16722388

Group type: EXPERIMENTAL
Intervention: Yanshu injection combining with chemotherapy
Number of subjects: 85